Novo Nordisk vs Vertex (NVO vs VRTX)

Novo Nordisk (NVO) vs Vertex (VRTX) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Novo Nordisk (NVO) and Vertex (VRTX) compete in healthcare and pharma. Here are Novo Nordisk and Vertex side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Novo Nordisk or Vertex.

Novo Nordisk vs Vertex: the figures

Novo Nordisk and Vertex figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Novo Nordisk or Vertex figure is not available, and we never estimate it.

3 key differences between Novo Nordisk and Vertex

1. Valuation: Vertex trades at 36.8x its annual earnings and Novo Nordisk at 10.3x; the market pays more for each dollar of Vertex profit, usually because it expects more growth.
2. Dividend: Novo Nordisk pays a dividend yielding 4.47% and Vertex pays none.
3. Growth: Vertex grew sales +11.8% year on year in its latest quarter, against +2.1% for Novo Nordisk.

Novo Nordisk or Vertex: which fits your profile

• If you want growth: Vertex is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Novo Nordisk pays the higher dividend relative to its price.
• If you prefer caution: Vertex has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Novo Nordisk trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither Novo Nordisk nor Vertex wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Novo Nordisk and Vertex make money

Novo Nordisk (NVO)

Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. The United States is its biggest market, ahead of Europe, China and the rest of the world. Its ADRs trade in New York. Full Novo Nordisk analysis.

Vertex (VRTX)

Vertex Pharmaceuticals earns most of its revenue from cystic fibrosis drugs such as Trikafta, sold as Kaftrio in Europe, and Alyftrek. It has broadened its lineup with Casgevy, a gene-editing therapy for sickle cell disease, and Journavx, a non-opioid pain medicine. The United States and Europe are its biggest markets. Full Vertex analysis.

Frequently asked questions: Novo Nordisk vs Vertex

Is Novo Nordisk or Vertex the better stock?

Choosing between Novo Nordisk and Vertex depends on what you are looking for. Vertex is growing faster right now, and Novo Nordisk trades on the lower P/E. Fintols does not tell you whether to buy Novo Nordisk or Vertex: it shows you the differences so you can decide.

Which pays a higher dividend, Novo Nordisk or Vertex?

As of November 4, 2026, Novo Nordisk yields 4.47% and Vertex pays none. Also check how much of their profit Novo Nordisk and Vertex pay out: if it is more than they earn, it cannot last.

Which is more expensive, Novo Nordisk or Vertex?

On P/E, Vertex (36.8x) is more expensive than Novo Nordisk (10.3x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both Novo Nordisk and Vertex?

Yes. Many people spread their money across several companies, such as Novo Nordisk and Vertex, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Novo Nordisk or Vertex.

More comparisons with Novo Nordisk or Vertex

• Boston Scientific vs Novo Nordisk
• Novo Nordisk vs Stryker
• Boston Scientific vs Vertex
• Stryker vs Vertex

More companies like Novo Nordisk and Vertex: healthcare and pharma stocks. Educational content about Novo Nordisk and Vertex, not investment advice.